Patient Stories
Stories of Hope
Find stories of hope, told by the people who motivate us every day to continue changing the standard in cancer care.
Emily
Chuck
Celeste
Our process
Cell Therapy Explained in 5 Steps
Each cell therapy we develop is uniquely designed for each patient, harnessing the power of the immune system to target and attack cancer. Our CAR T-cell therapy manufacturing process includes these 5 steps:
STEP 1
STEP 2
STEP 3
STEP 4
STEP 5
Our Therapies
our pipeline
Our careers
Kite News
Newsroom
Recent Press Releases
-
December 09, 2024
Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024 -
December 09, 2024
Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
Recent Company Statements
-
October 16, 2024
Kite Appoints Gallia Levy, MD, PhD, as Global Head of Clinical Development and Laura Alquist as Global Head of Technical Operations -
October 3, 2024
Kite Receives U.S. FDA Regenerative Medicine Advanced Therapy Designation for the Evaluation of Yescarta® (axicabtagene ciloleucel) CAR T-cell Therapy as First-Line Treatment for Patients with High-Risk Large B-Cell Lymphoma